News
July 20, 2009
HOLDEN, MA - Hygeia Therapeutics Inc. (the "Company" or "Hygeia") today
announced that it has enhanced its pipeline with the acquisition of a series of
potent topical anti-androgens. The lead compound, HYG-440, is expected to
lack systemic effects. The addition of the series of anti-androgens covering
four different structural classes, adds to the Company portfolio of topically
acting hormone receptor modulators. HYG-440 will undergo preclinical
development for the treatment of androgen-dependent dermatological
disorders such as acne, hirsutism and androgenic alopecia.
The anti-androgens were licensed from Yale University following approval of
the transaction by Hygeia stockholders earlier this week. The asset acquisition,
announced on July 16, 2009, is an important element of Hygeia's strategy for
creating shareholder value. Hygeia shareholders will gain access to an
important pipeline asset. Terms of the acquisition were not disclosed.
"We are excited about Hygeia's future, and are encouraged by the positive
reaction we have received to this transaction from our investors, scientific
advisory board and thought leaders in dermatology and women's health", said
Yael Schwartz, Ph.D., President and Chief Executive Officer of Hygeia. "This
acquisition combines decades of scientific experience, drug research, and
success in discovering numerous promising topical drug candidates. It
provides us with access to potentially lucrative corporate partnerships
interested in safe and efficacious topical hormone modulators in the
therapeutic areas of dermatology and women's health."
November 2007
WORCESTER, MA -- Hygeia Therapeutics, Inc. (formerly Orcas Therapeutics, Inc.)
announced that it has signed an exclusive worldwide license with Yale
University for the development and commercialization of a novel, safe, locally
acting synthetic estrogen for the topical treatment of vaginal wall atrophy,
skin thinning and wrinkling. Yale will receive an undisclosed upfront payment
with additional milestone payments from Hygeia as various development
milestones and revenue targets are met.
The product licensed from Yale is a first-in-class synthetic estrogen for topical
use that was invented by Dr. Richard Hochberg. This product is expected to be
devoid of the untoward systemic effects associated with use of other oral and
topical estrogen products.
“This agreement with Yale reflects their confidence in our ability to successfully
advance the patented topical synthetic estrogen technology through
preclinical development and into the clinic,” noted Hygeia Therapeutics’ CEO,
Dr. Yael Schwartz.
Forward-Looking Statements
These releases contain forward-looking statements that involve risks and
uncertainties. Hygeia cautions readers that any forward-looking information is
not a guarantee of future performance and actual results could differ
materially from those contained in the forward-looking information. Words such
as "expect," "estimate," "project," "potential," and similar expressions are
intended to identify such forward-looking statements. Such forward looking
statements include, but are not limited to, statements about Hygeia and its
plans, objectives, expectations and intentions and other statements that are
not historical facts. Hygeia product candidates may have unexpected
adverse side effects or inadequate therapeutic efficacy; and positive results
in clinical trials may not be sufficient to obtain FDA approval. There can be no
assurance that any product in the company's product pipeline will be
successfully developed or manufactured, that final results of clinical studies
will be supportive of regulatory approvals required to market licensed
products, or that any of the forward-looking information provided herein will be
proven accurate.
Hygeia disclaims any intent or obligation to update these forward-looking
statements beyond the date of this release. This caution is made under the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995.
HOLDEN, MA - Hygeia Therapeutics Inc. (the "Company" or "Hygeia") today
announced that it has enhanced its pipeline with the acquisition of a series of
potent topical anti-androgens. The lead compound, HYG-440, is expected to
lack systemic effects. The addition of the series of anti-androgens covering
four different structural classes, adds to the Company portfolio of topically
acting hormone receptor modulators. HYG-440 will undergo preclinical
development for the treatment of androgen-dependent dermatological
disorders such as acne, hirsutism and androgenic alopecia.
The anti-androgens were licensed from Yale University following approval of
the transaction by Hygeia stockholders earlier this week. The asset acquisition,
announced on July 16, 2009, is an important element of Hygeia's strategy for
creating shareholder value. Hygeia shareholders will gain access to an
important pipeline asset. Terms of the acquisition were not disclosed.
"We are excited about Hygeia's future, and are encouraged by the positive
reaction we have received to this transaction from our investors, scientific
advisory board and thought leaders in dermatology and women's health", said
Yael Schwartz, Ph.D., President and Chief Executive Officer of Hygeia. "This
acquisition combines decades of scientific experience, drug research, and
success in discovering numerous promising topical drug candidates. It
provides us with access to potentially lucrative corporate partnerships
interested in safe and efficacious topical hormone modulators in the
therapeutic areas of dermatology and women's health."
November 2007
WORCESTER, MA -- Hygeia Therapeutics, Inc. (formerly Orcas Therapeutics, Inc.)
announced that it has signed an exclusive worldwide license with Yale
University for the development and commercialization of a novel, safe, locally
acting synthetic estrogen for the topical treatment of vaginal wall atrophy,
skin thinning and wrinkling. Yale will receive an undisclosed upfront payment
with additional milestone payments from Hygeia as various development
milestones and revenue targets are met.
The product licensed from Yale is a first-in-class synthetic estrogen for topical
use that was invented by Dr. Richard Hochberg. This product is expected to be
devoid of the untoward systemic effects associated with use of other oral and
topical estrogen products.
“This agreement with Yale reflects their confidence in our ability to successfully
advance the patented topical synthetic estrogen technology through
preclinical development and into the clinic,” noted Hygeia Therapeutics’ CEO,
Dr. Yael Schwartz.
Forward-Looking Statements
These releases contain forward-looking statements that involve risks and
uncertainties. Hygeia cautions readers that any forward-looking information is
not a guarantee of future performance and actual results could differ
materially from those contained in the forward-looking information. Words such
as "expect," "estimate," "project," "potential," and similar expressions are
intended to identify such forward-looking statements. Such forward looking
statements include, but are not limited to, statements about Hygeia and its
plans, objectives, expectations and intentions and other statements that are
not historical facts. Hygeia product candidates may have unexpected
adverse side effects or inadequate therapeutic efficacy; and positive results
in clinical trials may not be sufficient to obtain FDA approval. There can be no
assurance that any product in the company's product pipeline will be
successfully developed or manufactured, that final results of clinical studies
will be supportive of regulatory approvals required to market licensed
products, or that any of the forward-looking information provided herein will be
proven accurate.
Hygeia disclaims any intent or obligation to update these forward-looking
statements beyond the date of this release. This caution is made under the safe
harbor provisions of the Private Securities Litigation Reform Act of 1995.
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| |
 |
| Copyright © 2009 Hygeia Therapeutics, Inc. All Rights Reserved. |
